Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II)

Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression

  • 21 views
  • 04 Jun, 2022
  • 30 locations
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration

luteinizing hormone
neutrophil count
bone scan
bisphosphonate
endocrine therapy
  • 149 views
  • 04 Jun, 2022
  • 12 locations
CRAFT: The NCT-PMO-1602 Phase II Trial

revealed genetic alterations in a substantial proportion of patients including (i) alterations that lead to aberrant activation of BRAF, ERBB2, ALK, and the PI3K-AKT and MAPK pathways and (ii) changes that

  • 0 views
  • 15 Jun, 2022
  • 3 locations
Multidisciplinary Support To Access Living Donor Kidney Transplant-Pilot (MuST AKT)

. The investigators have developed the Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention to support patients in identifying and communicating with their social

  • 0 views
  • 22 Mar, 2022
  • 1 location
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

>To explore molecular correlates of the relationship between mutations in Akt/ PIK3CA/PTEN pathway and response to AZD5363 +Olaparib+ Durvalumab To understand the role of tumour

  • 0 views
  • 22 Jan, 2021
  • 1 location
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

There is no clinical study on epidermal growth factor receptor tyrosine kinase inhibitors has been systematically conducted in adenoid cystic carcinoma. This is a phase II study EGFR TKIs in adenoid cystic carcinoma to evaluate its efficacy in this disease.

Accepts healthy volunteers
  • 3 views
  • 15 Nov, 2021
  • 1 location
Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with recurrent or progressive low-grade glioma.

  • 24 views
  • 07 Nov, 2020
  • 1 location
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then homologous-recombination deficiency patients. Limited data revealed the ORR was …

  • 0 views
  • 25 Mar, 2022
  • 1 location
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

This pilot trial studies how rigsertib sodium works in treating patients with Recessive Dystrophic Epidermolysis bullosa (RDEB) with locally advanced Squamous Cell Carcinoma (SCC). Rigosertib may selectively target Epidermolysis bullosa (EB) cancer cells while leaving normal EB cells unaffected.

  • 0 views
  • 08 Sep, 2021
  • 1 location
Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism (Glucagon)

Purpose/Objectives: To investigate the effect of hyperglucagonemia on insulin action, particularly on adipose tissue. Research Design/Plan: Normal glucose tolerant subjects will be studied. Study subjects will receive a continuous glucagon infusion for 12 hours. Following glucagon infusion, subjects will receive prime-continuous tracer infusions for additional 4 hours to measure adipocyte …

Accepts healthy volunteers
  • 3 views
  • 01 Mar, 2022
  • 2 locations